![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/16bc98940a34f0991f9ca5e7ccbfa6889fec078f-1634x909.jpg?w=350&fit=crop&auto=format)
|Videos|December 6, 2022
Regulatory Considerations for Cell & Gene Therapies
Author(s)PPD
The first segment of this five-part PPD Tech Talk series on A CMC Roadmap for Cell and Gene Therapies, Katherine Hanson, Ph.D., associate director at PPD Laboratory services, GMP Lab, discusses regulatory considerations for cell and gene therapies.
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Related Content
![[Rishi Pimentel, gChem]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/01d391920288b8bd8b751988988b5a6544a6ddaa-1629x908.jpg?w=350&fit=crop&auto=format)
![[Nigel Langley]](https://cdn.sanity.io/images/0vv8moc6/pharmtech/e2c0137d8224aaa1f14c0f1af43b58d21f4541dd-1768x904.jpg?w=350&fit=crop&auto=format)
Trending on Pharmaceutical Technology
1
Sustainability and Stability in Excipients
2
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
3
Turning Real-World Data into Actionable Drug Development Insights With AI
4
Why Sound Science Is Pharma's Best Defense Against Regulatory Shifts
5
